Endo International plc: directors' dealings · United States · SEC (Form 4)

About Endo International plc

Endo International plc was historically a U.S.-listed specialty pharmaceutical company traded on the NASDAQ under ticker ENDP, with operations centered in the United States. The company was incorporated in Ireland in 2013 and re-registered as a public limited company in 2014, while maintaining key corporate and operational footprints in Malvern, Pennsylvania, and Dublin, Ireland. Its business model combined branded specialty pharmaceuticals with a meaningful generics platform, with particular exposure to sterile injectables, hospital-focused aseptic medicines, and selected branded therapies for niche medical conditions. ([endo.com](https://www.endo.com/company/contact-locations/?utm_source=openai)) From an industry perspective, Endo occupied a middle-ground position in healthcare: more differentiated than a pure generics manufacturer, but not a broad-based large-cap innovator. The company emphasized capabilities in development, manufacturing, and commercialization, and highlighted product categories such as sterile injectables, aseptic products, and ready-to-administer/ready-to-use formulations. Its portfolio was designed to serve hospitals, specialists, and pharmaceutical distribution channels, with a focus on value-added products where operational reliability, quality, and regulatory execution matter as much as pricing. ([endo.com](https://www.endo.com/products-and-capabilities/products/?utm_source=openai)) Geographically, Endo was predominantly U.S.-oriented, with the United States as its core commercial market and manufacturing base, complemented by operations in Ireland and India. The company maintained multiple U.S. facilities across Pennsylvania, New Jersey, New York, and Michigan, reflecting a supply chain built to support domestic healthcare demand. For investors, Endo should be viewed as a complex turnaround and restructuring story rather than a conventional growth pharma name, particularly given its long-running litigation, regulatory, and balance-sheet challenges. ([endo.com](https://www.endo.com/company/contact-locations/?utm_source=openai)) A major recent development materially changed the company’s identity. In July 2025, Endo and Mallinckrodt completed a merger, after which the combined company spun off its generics and sterile injectables business as an independent company, Par Health, and later rebranded the specialty therapeutics business as Keenova Therapeutics in November 2025. As a result, the historic Endo International plc profile is now largely a legacy reference point, but it remains relevant for interpreting SEC filings, including Form 4 insider transaction activity, and for understanding the company’s evolution in the U.S. healthcare sector. ([endo.com](https://www.endo.com/?utm_source=openai))